Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: Report of two cases from South America

Leukemia and Lymphoma

Volumn 52, Issue 1, 2011, Pages 153-156

  Beltran, Brady E ^a   Castillo, Jorge J ^b   Salas, Renzo ^a   Quiñones, Pilar ^a   Morales, Domingo ^a   Cotrina, Esther ^a   Miranda, Roberto N ^c   Sotomayor, Eduardo M ^d  

^a HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

^b MIRIAM HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; KI 67 ANTIGEN; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; BRAIN LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; EPSTEIN BARR VIRUS; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS CARCINOGENESIS;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; PREDNISOLONE; PROGNOSIS; SOUTH AMERICA; VINCRISTINE;

EID: 78651330964     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.528094     Document Type: Article

References (13)

1. Nakamura S, Jaffe ES, Swerdlow SH. EBV positive diffuse large B-cell lymphoma of the elderly. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 243-244.
2. Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 2007;13:5124-5132.
3. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007;110:972-978.
4. Yoshino T, Nakamura S, Matsuno Y, et al. Epstein-Barr virus involvement is a predictive factor for the resistance to chemo-radiotherapy of gastric diffuse large B-cell lymphoma. Cancer Sci 2006;97:163-166.
5. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23: 4117-4126.
6. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.
7. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
8. Gibson SE, Hsi ED. Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerm-inal center B-cell phenotype. Hum Pathol 2009;40:653-661.
9. Morales D, Beltran B, De Mendoza FH, et al. Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leuk Lymphoma 2010;51:66-72.
10. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
11. Seki R, Ohshima K, Fujisaki T, et al. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2009;100:1842-1847.
12. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008;359:2313-2323.
13. Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lympho-ma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-5502.